The Crystec team have pioneered the development of mSAS^®, a modified Supercritical Anti-Solvent process. mSAS^® is a powerful technology for engineering particles to improve the bioavailability, stability, and delivery of small molecule and large molecule therapeutics.

This unique platform enables the size and shape of particles to be finely tuned. Where required, more than one drug can be combined in a particle, or excipients incorporated in the particle to further enhance performance and reduce manufacturing complexity. We design particles with the medicine in mind, hence Performance in Every Particle^®.